These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Juvenile OLFM4-null mice are protected from sepsis. Stark JE; Opoka AM; Mallela J; Devarajan P; Ma Q; Levinsky NC; Stringer KF; Wong HR; Alder MN Am J Physiol Renal Physiol; 2020 Mar; 318(3):F809-F816. PubMed ID: 32068457 [TBL] [Abstract][Full Text] [Related]
6. Olfactomedin-4 Is a Candidate Marker for a Pathogenic Neutrophil Subset in Septic Shock. Alder MN; Opoka AM; Lahni P; Hildeman DA; Wong HR Crit Care Med; 2017 Apr; 45(4):e426-e432. PubMed ID: 27635771 [TBL] [Abstract][Full Text] [Related]
7. Olfactomedin 4 marks a subset of neutrophils in mice. Alder MN; Mallela J; Opoka AM; Lahni P; Hildeman DA; Wong HR Innate Immun; 2019 Jan; 25(1):22-33. PubMed ID: 30537894 [TBL] [Abstract][Full Text] [Related]
8. Olfactomedin-4-Positive Neutrophils in Neonates: Link to Systemic Inflammation and Bronchopulmonary Dysplasia. Al Gharaibeh FN; Kempton KM; Alder MN Neonatology; 2023; 120(1):40-48. PubMed ID: 36549285 [TBL] [Abstract][Full Text] [Related]
9. Olfactomedin-4 in digestive diseases: A mini-review. Wang XY; Chen SH; Zhang YN; Xu CF World J Gastroenterol; 2018 May; 24(17):1881-1887. PubMed ID: 29740203 [TBL] [Abstract][Full Text] [Related]
10. The human neutrophil subsets defined by the presence or absence of OLFM4 both transmigrate into tissue in vivo and give rise to distinct NETs in vitro. Welin A; Amirbeagi F; Christenson K; Björkman L; Björnsdottir H; Forsman H; Dahlgren C; Karlsson A; Bylund J PLoS One; 2013; 8(7):e69575. PubMed ID: 23922742 [TBL] [Abstract][Full Text] [Related]
11. Olfactomedin 4 inhibits cathepsin C-mediated protease activities, thereby modulating neutrophil killing of Staphylococcus aureus and Escherichia coli in mice. Liu W; Yan M; Liu Y; McLeish KR; Coleman WG; Rodgers GP J Immunol; 2012 Sep; 189(5):2460-7. PubMed ID: 22844115 [TBL] [Abstract][Full Text] [Related]
12. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer. Liu W; Rodgers GP Cancer Metastasis Rev; 2016 Jun; 35(2):201-12. PubMed ID: 27178440 [TBL] [Abstract][Full Text] [Related]
13. Plasma levels of OLFM4 in normals and patients with gastrointestinal cancer. Clemmensen SN; Glenthøj AJ; Heebøll S; Nielsen HJ; Koch C; Borregaard N J Cell Mol Med; 2015 Dec; 19(12):2865-73. PubMed ID: 26416558 [TBL] [Abstract][Full Text] [Related]
14. The Olfactomedin-4-Defined Human Neutrophil Subsets Differ in Proteomic Profile in Healthy Individuals and Patients with Septic Shock. Lundquist H; Andersson H; Chew MS; Das J; Turkina MV; Welin A J Innate Immun; 2023; 15(1):351-364. PubMed ID: 36450268 [TBL] [Abstract][Full Text] [Related]
15. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers. Yu L; Wang L; Chen S Neoplasma; 2011; 58(1):9-13. PubMed ID: 21067260 [TBL] [Abstract][Full Text] [Related]
16. Olfactomedin 4 Is a Biomarker for the Severity of Infectious Diseases. Liu W; Rodgers GP Open Forum Infect Dis; 2022 Apr; 9(4):ofac061. PubMed ID: 35291445 [TBL] [Abstract][Full Text] [Related]
17. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer. Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767 [TBL] [Abstract][Full Text] [Related]
18. Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma. Suzuki L; Ten Kate FJC; Gotink AW; Stoop H; Doukas M; Nieboer D; Spaander MCW; van Lanschot JJB; van Wijnhoven BPL; Koch AD; Bruno MJ; Looijenga LHJ; Biermann K PLoS One; 2019; 14(7):e0219494. PubMed ID: 31283789 [TBL] [Abstract][Full Text] [Related]